MediVector, Fujifilm U.S. Flu Drug Trial Reaches Key Recruitment Point
This article was originally published in PharmAsia News
MediVector and Japan partner Fujifilm, which are developing a drug to treat drug-resistant influenza strains, said they have now enrolled more than half the planned participants in U.S. Phase III clinical trials with their candidate, with an approval filing possible next year.